Dapsone (Avlosulfan)

Category:

  • Miscellaneous

Description:

  • Antiprotazoal

Indications:

  • All forms of leprosy (Hansen’s disease), except for cases of proven dapsone resistance

  • Dermatitis herpetiformis

Precautions:

  • Pregnancy category C; excreted in breast milk, may cause reaction in infants

  • Renal disease, G-6-PD deficiency

  • Anemia, severe cardiopulmonary disease, methemoglobin reductase deficiency

Adverse Reactions (Side Effects):

  • CNS: headache, insomnia, paresthesia, peripheral neuropathy, psychosis, vertigo

  • EENT: blurred vision, optic neuritis, photophobia, tinnitus

  • GI: abdominal pain, anorexia, nausea, vomiting

  • GU: nephrotic syndrome, proteinuria, renal papillary necrosis

  • HEME: agranulocytosis, aplastic anemia, hemolytic anemia

  • SKIN: drug-induced systemic lupus erythematosis, photosensitivity

 

Dosage:

Administered orally

  • Adult:            

    • Leprosy: PO 50-100mg daily for 3-10 years (addition of rifampin 600mg daily for 1st 6 months is recommended)

    • Dermatitis herpetiformis: PO 50mg initially; increase to 300mg daily or higher to achieve full control; reduce dosage to minimum level as soon as possible

  • Child:            

    • Leprosy: PO 1-2 mg/kg/day; max 100mg daily

Special considerations:

  • Use in conjunction with rifampin or clofazimine to prevent development of drug resistance and reduce infectiousness of patient with leprosy more quickly

  • Full therapeutic effects on leprosy may not occur for several months; compliance with dosage schedule, duration is important

 

 

 

Home  ·  Military Medicine  ·  Sick Call  ·  Basic Exams  ·  Medical Procedures  ·  Lab and X-ray  ·  The Pharmacy  ·  The Library  ·  Equipment  ·  Patient Transport  ·  Medical Force Protection  ·  Operational Safety  ·  Operational Settings  ·  Special Operations  ·  Humanitarian Missions  ·  Instructions/Orders  ·  Other Agencies  ·  Video Gallery  ·  Forms  ·  Web Links  ·  Acknowledgements  ·  Help  ·  Feedback

Approved for public release; Distribution is unlimited.

The information contained here is an abbreviated summary. For more detailed and complete information, consult the manufacturer's product information sheets or standard textbooks.

Source: Operational Medicine 2001, Health Care in Military Settings, NAVMED P-5139, May 1, 2001, Bureau of Medicine and Surgery, Department of the Navy, 2300 E Street NW, Washington, D.C., 20372-5300.

Bureau of Medicine and Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300

Operational Medicine
 Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
  January 1, 2001

United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323

*This web version is provided by The Brookside Associates, LLC.  It contains original contents from the official US Navy NAVMED P-5139, but has been reformatted for web access and includes advertising and links that were not present in the original version. The medical information presented was reviewed and felt to be accurate in 2001. Medical knowledge and practice methods may have changed since that time. Some links may no longer be active. This web version has not been approved by the Department of the Navy or the Department of Defense. The presence of any advertising on these pages does not constitute an endorsement of that product or service by either the US Department of Defense or the Brookside Associates. The Brookside Associates is a private organization, not affiliated with the United States Department of Defense.

© 2015, Brookside Associates, LLC. All rights reserved

Other Brookside Products

 

 

Advertise on this site